Local Prescribing Information (Rheumatology):
Tocilizumab Injection IV and SC [Actemra®]
Rituximab Injection [Ristova® and Ikgdar®]
Safety Update Information for Healthcare Professionals (Rheumatoid Arthritis):
Actemra® (Tocilizumab): A new Important Identified Risk: Hepatotoxicity
Disclaimer - Kindly note that it takes approximately up to 6 months to implement the revised PI in commercial stocks imported into India after submission to the health authorities. All PIs notified to or approved by the CDSCO are published on this website for all the HCPs prescribing Roche drugs within 10 calendar days.